BioStock: Aptahem on the need for more effective sepsis treatments

Biotechnology company Aptahem is developing Apta-1, a drug candidate whose purpose is to reduce the high mortality and severe tissue damage that can occur in sepsis. BioStock contacted Luiza Jedlina, Chief Scientific Officer and co-founder of Aptahem, to talk about the need for better treatment options than antibiotics.  

Read the full interview with Luiza Jedlina at biostock.se:

https://www.biostock.se/en/2023/04/aptahem-on-the-need-for-more-effective-sepsis-treatments/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/